OCUMENSION THERAPEUTICS

Insiders Ocumension Therapeutics

Equities

1477

KYG674111011

Delayed Hong Kong S.E. Other stock markets 23:01:25 2024-05-12 EDT			5-day change	1st Jan Change
6.9 ^HKD	+1.62%		-3.50%	+3.29%

04-15	Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug	MT
04-15	Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eyepoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing	12-08	MT
Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023	23-09-29	CI
Ocumension Therapeutics Announces Executive Changes	22-06-15	CI
Ocumension Therapeutics Appoints Mr. Zhenyu Zhang as Independent Non-Executive Director, the Chairman of the Remuneration Committee and a Member of the Nomination Committee and Audit Committee	22-04-08	CI
Ocumension Therapeutics Announces Demise of Lianming HE, Independent Non-Executive Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee	22-03-31	CI
Ocumension Therapeutics Announces Re-Designation of Executive Directors as Non-Executive Directors	21-07-20	CI
Ocumension Therapeutics Announces Board Changes	21-03-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW